Search - tctmd.com

Displaying 1 - 20 of 577

Sort: Relevancy | Date

News Opinion CV Team Dispatch

November 2025 Dispatch for the CV Team

L.A. McKeown

November 24, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Opinion CV Team Dispatch

October 2025 Dispatch for the CV Team

L.A. McKeown

October 25, 2025

News Daily News

Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients

Caitlin E. Cox

October 16, 2025

News Daily News

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Michael O'Riordan

October 10, 2025

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

Michael O'Riordan

October 02, 2025

News Opinion CV Team Dispatch

September 2025 Dispatch for the CV Team

L.A. McKeown

September 30, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

L.A. McKeown

September 09, 2025

News Conference News ESC 2025

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

Caitlin E. Cox

August 29, 2025

News Daily News

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Yael L. Maxwell

August 18, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

Heart Disease Treatment Costs $100 Billion per Year in the US

L.A. McKeown

July 30, 2025

News Opinion CV Team Dispatch

July 2025 Dispatch for the CV Team

L.A. McKeown

July 24, 2025

News Conference News SCCT 2025

AI-QCT Possibly Lessens Gap Between Ideal vs Actual Care for Patients at Risk of ASCVD

Yael L. Maxwell

July 22, 2025

Advertisement

November 2025 Dispatch for the CV Team

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

October 2025 Dispatch for the CV Team

Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Evolocumab Wins for Primary Prevention in VESALIUS-CV

Risk Factors Present in Nearly All Patients Who Develop CVD

September 2025 Dispatch for the CV Team

CVD Still the Leading Cause of Death and Disease Globally

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Heart Disease Treatment Costs $100 Billion per Year in the US

July 2025 Dispatch for the CV Team

AI-QCT Possibly Lessens Gap Between Ideal vs Actual Care for Patients at Risk of ASCVD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content